As can be seen in the letter below, according to the Immunisation Advisory Centre (IMAC) at Auckland University: “There are no serious events believed to be caused by the [Gardasil] vaccine. The deaths reported following vaccination are mainly motor vehicle accidents and other unrelated events.”
IMACs Ms Petousis-Harris made this ridiculous claim in a letter to The Whangarei Report on February the 19th 2009, in response to a letter I had published about the thousands of adverse reactions and precancerous lesions associated with Gardasil.
One has to wonder why the taxpayer-funded IMAC will not disclose the facts about the number of adverse reactions and deaths that have been reported, when the mainstream media will. In this CBS report that aired on the 6th of February, it was mentioned that the National Vaccine Information Center, a private vaccine-safety group, compared Gardasil adverse events to another vaccine, one also given to young people, but for meningitis. Gardasil had three times the number of Emergency Room visits – more than 5,000. As you can see, this news report also mentions that there have been 29 fatalities reported in two years in association with Gardasil, yet according to Helen Petousis-Harris “to suggest these are vaccine related is mischievous.”
Also, while Petousis-Harris claims that there is no evidence that Gardasil increases the risk of precancerous lesions, even the Gardasil insert, which can be read at Merck’s own website, indicates that it does do so. On page 14 of the insert it states: “Infected women may already have CIN 2/3 or AIS at vaccination onset and some will develop CIN 2/3 or AIS during follow-up, either related to a vaccine…”
In relation to this matter, a Judicial Watch report asserts:
“The possibility that Gardasil could make HPV infections worse is very serious, and a matter of concern with both critics of the vaccine and the FDA.”
A background document produced by the FDA’s VRBPAC in May 2006 states:
“There were two important concerns that were identified during the course of the efficacy review of this BLA [biologics license application]. One was the potential for Gardasil to enhance disease among a subgroup of subjects
who had evidence of persistent infection with vaccine relevant HPV types at baseline. The other concern was the observations of CIN 2/3 [cervical intraepithelial neoplasia, abnormal cell changes in moderate stage] or worse cases due to HPV types not contained in the vaccine. These cases of disease due to other HPV types have the potential to counter the efficacy results of Gardasil for the HPV types contained in the vaccine . . . The results of exploratory subgroup analyses . . . suggested a concern that subjects who were . . . positive for the vaccine-relevant HPV types had a greater number of CIN 2/3 or worse cases.
It further states on page 6 of the report:
“A chart in the committee’s report revealed that efficacy in subjects already exposed to “relevant HPV types” had an observed efficacy rate of -44.6%. The disturbing efficacy rate raises questions as to who should be receiving the vaccine, and why the FDA allows Gardasil to be administered without prescreening for HPV..”
So there you go. Gardasil may cause precancerous lesions in those who already have the HPV and it is all there in plain print to read. Given the fact that children are being sexually abused, and thus potentially infected with the HPV, one would think that this matter would be of great concern to IMAC and they would wish to inform the public of this serious issue.
The Judicial Watch document is in full here. If you are willing to take a risk, which was implied by the web page at the time of writing, click on “Ignore this warning” at the bottom right-hand side of the red panel.
The Gardasil Insert http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf